COVID-19 Vaccine

Phase 2 (Data)

Exp Date


Amp Volatility Score

Catalyst Info & Data Links


  • TBA



  • NVX-CoV2373, a stable, prefusion protein made using Novavax’ proprietary nanoparticle technology

  • Matrix-M™ adjuvant will be incorporated with NVX-CoV2373 in order to enhance immune responses and stimulate high levels of neutralizing antibodies

  • NVX-CoV2373 was shown to be highly immunogenic in animal models measuring spike protein-specific antibodies, antibodies that block the binding of the spike protein to the receptor and wild-type virus neutralizing antibodies. High levels of spike protein-specific antibodies with ACE-2 human receptor binding domain blocking activity and SARS-CoV-2 wild-type virus neutralizing antibodies were observed after a single immunization.

  • (Source)

Updated by HC

#NVAX, #NVX-CoV2373, #COVID-19, #Vaccine

Prior Data (click to view full image)


Trial Design / Revenue (click to view full image)


Recent Posts

See What The Community Is Saying - Click To See Full Post

NVAX - NVX-CoV2373 Phase 1 Dat...

Novavax Announces Positive Phase 1 Data for its COVID-19 Vaccine Candidate. Scientific Summary: Phase 1 portion of the Phase 1/2 clinical trial evaluated two doses of Novavax’ COVID-19 vaccine across...

Will the current Coronavirus b...

As we started to look at NVAX, one of the recent stocks whose Coronavirus vaccine work has created some hype, we looked deeper into this question. See what we learned about influenza and SARS in our a...

NVAX COVID-19 Vaccine selected...

Novavax was selected to participate in Operation Warp Speed (OWS), a U.S governmental program that aims to begin delivering millions of doses of a COVID-19 vaccine in 2021. Novavax was rewarded $1.6 m...

Coronavirus - As the worldwide...

We have stayed out of stock trades of companies whose stock has moved directly related to new vaccine and therapeutic activities related to Coronavirus because we try to stay out of hype trades. We ar...

Why didn' NVAX move up more on...

We are surprised that NVAX isn't up more today (now up around 15% and market overall up around 1/2 of that) on positive phase 3 data for its flu vaccine candidate. Thought the market would read that ...

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon